Randomized phase II trial and tumor mutational spectrum analysis from cabozantinib versus chemotherapy in metastatic uveal melanoma (Alliance A091201)
- Citation:
- Clin Cancer Res vol 26 (4) 804-11
- Year:
- 2020
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Program:
- OGC
- Primary Committee:
- Experimental
- Sec. Committees:
- Pharmas:
- Exelixis
- Grants:
- U10CA180821, U10CA180882, U10CA180836, U24CA196171, UG1CA189960, U10CA180863 (CCTG), W81XWH-17-1-0265; P30 CA014599; NIH/NIGMS T32GM007019,
- Corr. Author:
- Authors:
- Jason J. Luke Daniel J. Olson Jacob B. Allred Carrie A. Strand Riyue Bao Yuanyuan Zha Timothy Carll Brian W. Labadie Bruno R. Bastos Marcus Butler Davide Hogg Pamela Munster Gary K. Schwartz
- Networks:
- 11030, CA136, COLUMBIA, FL310, LAPS-IL057, LAPS-MN026, LAPS-PA015
- Study
- Alliance-A091201
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: